LOGIN  |  REGISTER

Autolus Therapeutics announces participation in upcoming conferences

November 06, 2023 | Last Trade: US$3.08 0.07 2.33

LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its participation in three upcoming conferences in November.

Truist Securities BioPharma Symposium
Panel: Considerations for an Oncology Company’s Autoimmune Side Hustle
Date and time: 9 November 2023, 11:40am ET / 16:40pm GMT
Location: New York, USA
Presenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics

Jefferies London Healthcare Conference  
Fireside Chat
Date and time: 16 November 2023, 4:00am ET / 9:00am GMT
Location: London, UK
Presenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics

Piper Sandler 35th Annual Healthcare Conference
Fireside Chat
Date and time: 28 November 2023, 11:30am ET/ 16:30pm GMT
Location: New York, USA
Presenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics

Find out more information about upcoming events and any webcast and replay details at: https://www.autolus.com/investor-relations/events/

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com

Contact:

Julia Wilson
+44 (0) 7818 430877
This email address is being protected from spambots. You need JavaScript enabled to view it.

Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
This email address is being protected from spambots. You need JavaScript enabled to view it.

Lauren Williams
Investase
+44 23 9438 7760
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Recursion

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB